Remove Clinical Research Remove FDA Remove Trials
article thumbnail

Beyond blood tests: The evolution of digital biomarkers in clinical research

Drug Discovery World

Digital biomarkers promise to transform preventive medicine and clinical trials, but also raise issues of security, regulation and potential disparities in access. Deepika Khedekar, Clinical Trial Lead at IQVIA, provides an overview of the pros and cons, and suggests a possible solution.

article thumbnail

Applying Artificial Intelligence to Transform the Patient Enrollment Paradigm in Clinical Research

PPD

AI also has the potential to incorporate real-world data (RWD) obtained from electronic health records (EHRs), medical claims or other data sources to inform the design and optimization strategy of clinical trials.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

GAO Report on Clinical Research Inspections Encourages FDA to Care for its Clinical Inspection Program

FDA Law Blog: Biosimilars

Richardson — While Covid is in the rear view for most of us, FDA has had a tough time shaking off the effects of the pandemic on its inspection output. In March 2020 , FDA temporarily postponed all foreign and domestic and routine surveillance facility inspections. Inspections went down—way down—during the pandemic.

article thumbnail

FDA approves Izervay for geographic atrophy

Drug Discovery World

The US Food and Drug Administration (FDA) has approved Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The FDA approval of Izervay is great news for the retina community and our patients suffering from GA.” GA impacts an estimated 1.5

article thumbnail

FDA approves first T cell therapy in solid tumours

Drug Discovery World

“Unresectable or metastatic melanoma is an aggressive form of cancer that can be fatal,” said Peter Marks, Director of the FDA’s Center for Biologics Evaluation and Research (CBER). Amtagvi is the first FDA-approved tumour-derived T cell immunotherapy. Among patients who were responsive to the treatment, 56.5%, 47.8%

article thumbnail

Early trial data supports neurodegenerative disease-modifying drug

Drug Discovery World

In addition to Allyx’s continued clinical development of ALX-001 in Alzheimer’s disease, the company has announced an expansion into Parkinson’s disease clinical research with the opening of an Investigational New Drug Application with the US Food and Drug Administration (FDA).

Disease 130
article thumbnail

$20 million in new funding to make clinical trials more inclusive

Drug Discovery World

Clinical trial technology platform Inato, based in Paris, France, has closed a $20 million Series A funding from investors including Cathay Innovation, Obvious Ventures, La Maison and Top Harvest Capital. With the new funding, Inato will advance its diversity product offering to meet the new FDA requirements.